Four dominant loci for the vascular responses by the antitumor polysaccharide, lentinan

Immunogenetics

Volumn 47, Issue 2, 1997, Pages 159-165

  Maeda, Yukiko Y ^a   Takahama, Sumiyo ^a   Yonekawa, Hiromichi ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Antitumor polysaccaride; Biological response modifiers; Lentinan; Lentinan responsive gene; Vascular dilation and hemorrhage

Indexed keywords

IMMUNOSTIMULATING AGENT; LENTINAN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL REACTIVITY; CHROMOSOME 6; GENE LOCATION; INTRAPERITONEAL DRUG ADMINISTRATION; MAJOR GENE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALIA;

EID: 0031985892     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510050341     Document Type: Article

References (18)

1. Bluhm, T. L. and Sarko, A. The triple helical structure of lentinan, a linear β-(1→3)-D-glucan. Can J Chem 55: 293-299, 1977
2. Chihara, G., Hamuro, J., Maeda, Y. Y., Arai, Y., and Fukuoka, F. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res 30: 2776-2781, 1970
3. Chihara, G., Maeda, Y. Y., and Hamuro, J. Current status and perspectives of immunomodulators of microbial origin. Int J Tiss Reac 4: 207-225, 1982
4. Czop, J. K. and Kay, J. Isolation and characterization of β-glucan receptors on human mononuclear phagocytes, J Exp Med 173: 1511-1520, 1991
5. Hamuro, J., Wagner, H., and Röllinghoff, M. β(1→3)glucans as a probe for T cell specific immune adjuvants. II. Enhanced in vitro generation of cytotoxic T lymphocytes. Cell Immunol 38: 328-335, 1978
6. Lander, E. and Kruglyak, L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nature Genetics 11: 241-247, 1995
7. Maeda, Y. Y. and Chihara, G. Lentinan, a new immunoaccelerator of cell-mediated responses. Nature 229: 634, 1971
8. Maeda, Y. Y., Chihara, G., and Ishimura, K. Unique increase of serum proteins and action of antitumour polysaccharides. Nature 252: 250-252, 1974
9. Maeda, Y. Y., Watanabe, S. T., Chihara, G., and Rokutanda, M. T-cell mediated vascular dilation and hemorrhage induced by antitumor polysaccharides. Int J Immunopharmac 6: 493-501, 1984
10. Maeda, Y. Y., Watanabe, S. T., Chihara, C., and Rokutanda, M. Denaturation and renaturation of a β-1,6;1,3-glucan, lentinan, associated with expression of T-cell-mediated responses. Cancer Res 48: 671-675, 1988
11. Maeda, Y. Y., Sakaizumi, M., Moriwaki, K., and Yonekawa, H. Genetic control of the expression of two biological activities of an antitumor polysaccharide, lentinan. Int J Immunopharma 13: 977-986, 1991
12. Maeda, Y. Y., Takahama, S., Kohara, Y., and Yonekawa, H. Two genes controlling acute phase responses by the antitumor polysaccharide, lentinan. Immunogenetics 43: 215-219, 1996
13. Paul, W. E. and Seder, R. A. Lymphocytes responses and cytokines. Cell 76: 241-251, 1994
14. Sambrook, J., Fritsch, E. F., and Maniatis, T., (2nd edn) Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989
15. Suga, T., Shiio, T., Maeda, Y. Y., and Chihara, G. Antitumor activity of lentinan in murine syngeneic and autochthonous host and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 44: 5132-5137, 1984
16. Suga, T., Maeda, Y. Y., Uchida, H., Rokutanda, M., and Chihara, G. Macrophage-mediated acute-phase transport protein production induced by lentinan. Int J Immunopharma 8: 691-699, 1986
17. Suzuki, M., Iwashiro, M., Takatsuki, F., Kuribayashi, K., and Hamuro, J. Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor. Jpn Cancer Res 85: 409-417, 1994
18. Takatsuki, F., Namiki, R., Kikuchi, T., Suzuki, M., and Hamuro, J. Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilation and hemorrhage responses and antitumor activities. Int J Immunopharma 17: 465-474, 1995